Page 16 - Lupin

Pharma major Lupin announces launch of its diagnostics business

Homegrown pharma major Lupin Ltd on Friday announced the launch of its diagnostics arm as part of its strategy to provide integrated healthcare in India.

Drug maker Lupin inks pact to distribute, market Pegfilgrastim in Brazil

The company has entered into an exclusive distribution and marketing agreement with Biomm SA in Brazil

Drug firm Lupin launches generic Fenofibrate capsules in United States

Lupin on Wednesday said it has launched the capsules

Stocks to Watch: IRCTC, Airtel, SBI Cards, DLF, Tata Power, Lupin, Escorts

IRCTC and Bharti Airtel could be in focus owing to negative news flow, apart from the stocks that are likely to react to corporate earnings

Drug maker Lupin reports consolidated net loss of Rs 2,098 cr in Q2

Drug maker Lupin on Thursday reported a consolidated net loss

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Lupin recalls 2 hypertension drugs in US due to potential impurity

Drug firm Lupin on Thursday said its US-based arm is voluntarily recalling all batches of two hypertension drugs due to potential presence of a substance that could cause cancer. The company in a statement said that Lupin Pharmaceuticals Inc is voluntarily recalling lrbesartan tablets and lrbesartan and Hydrochlorothiazide tablets to the consumer level. The tablets have been recalled due to potential presence of N-nitrosoirbesartan impurity, a substance that could cause cancer. "As part of Lupin's ongoing assessment, analysis revealed that certain tested API batches (but not finished product batches) were above the specification limit for the impurity, N-nitrosoirbesartan," it added. Although the company has received no reports of illness that appear to relate to this issue, out of an abundance of caution it is recalling all batches of lrbesartan tablets USP 75mg, 150mg and 300mg and lrbesartan and Hydrochlorothiazide tablets USP, 150mg/12.Smg and 300mg/12.5mg in the US, Lupin ...

Stocks to watch: RIL, ZEEL, Sobha, Lupin, Nazar Tech, Titan, Inox Wind

Tata group firm Titan on Wednesday said it has witnessed a strong recovery in demand in the July-September quarter

Lupin gets tentative nod from USFDA to market generic Brexpiprazole tablets

The product is a generic version of Otsuka Pharmaceutical Co Ltd's Rexulti tablets in the same strengths

Stock picks by Osho Krishan of Anand Rathi: Buy Lupin, Gujarat Gas

LUPIN has corrected over 25 per cent from its 52 weeks high and is currently placed near its historical demand zone of 900 odd levels

Sensex ends 254 points lower, Nifty below 17,750; HDFC, RIL top drags

Stock Market LIVE: The broader indices, too, turned positive and gained up to 0.8 per cent

Stocks to watch: HDFC AMC, Airtel, Atul Auto, Lupin, Future Group stocks

NCLT allowed Kishore Biyani-led Future Group firms to hold meetings of its shareholders and creditors to seek approval for the sale of assets to Reliance Retail

Lupin forays into diagnostics business; launch expected next month

Also, Lupin is looking for franchise partners with an investment of Rs 2-5 lakh without any security deposit

Lupin's underperformance may continue on US-driven regulatory challenges

US sales trajectory, margins key triggers over the next couple of quarters

Lupin slips 4% as Goa plant gets 7 observations from the USFDA

These observations which has been under regulatory oversight for 4 years, and can impact investor sentiment although revenue will not be impacted in the near term, ICICI Securities note stated

Lupin's Goa plant gets 7 observations from USFDA, firm unperturbed

Says confident of resolving matter, does not share nature of observations

Lupin launches generic Duexis tablets in US to treat rheumatoid arthritis

Drug firm Lupin on Wednesday said it has launched generic Duexis tablets used to treat the symptoms of rheumatoid arthritis and osteoarthritis in the US market.

Lupin bets big on inhalation segment, plans to enter Chinese market

Lupin's portfolio and pipeline addresses 70 per cent of the entire market

Lupin gets tentative nod from USFDA to market partial-onset seizures drug

Drug firm Lupin on Monday said it has received tentative nod from the US health regulator to market its generic Brivaracetam tablets used for the treatment of partial-onset seizures

Lupin falls 7% post Q1 results, hits over three month low

The pharmaceutical company reported a disappointing April-June quarter (Q1FY22) performance on the margins front